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Abstract – Objectives: This research aims to assess the test–retest reliability, the
face, content and known groups validity, and responsiveness to change, of
OHIP-TMDs, a 22-item TMDs-specific version of the Oral Health Impact Profile
(OHIP).Methods: Test–retest reliability – A group of patients with TMDs (n = 20)
was administered OHIP-TMDs twice before initial consultation with a 2-week
interval. Face and content validity – Content validity index assessments were
undertaken with professionals and patients. Known groups validity –
Participants (n = 76) with confirmed Axis 1 RDC/TMD diagnoses completed
OHIP-TMDs prior to TMDs treatment. Their responses were compared, using
inferential statistics, with those of age- and gender-matched controls.
Responsiveness to change – Using the same 76 participants, a comparison was
made of OHIP-TMDs with OHIP-49 (order of administration randomized) both
at baseline and 3 months after starting treatment. Results: OHIP-TMDs showed
good test–retest reliability ICC [2,1] 0.805 (95% CI: 0.565, 0.918); good face and
content validity; significant differences (P < 0.001) between controls and
participants demonstrating known groups validity. Its responsiveness to
change was similar to OHIP-49. Conclusions: OHIP-TMDs is an appropriate
biopsychosocial, patient-centred, outcome measure for assessing QOL in
patients with TMDs. It is less than half the length of OHIP-49 and contains
proportionately more items relevant to TMDs.
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Temporomandibular disorders (TMDs) are a group
of painful musculoskeletal conditions affecting the
temporomandibular jaw joint (TMJ) and/or the mus-
cles of mastication (1). The evidence base for the
management of TMDs is problematic, and systematic
reviews on TMDs have consistently, and repeatedly,
called for standardized, reliable and reproducible
patient-centred outcome measures for TMDs to
advance and standardize trials of therapy (2–7).
There is a well-established association between
TMDs symptoms, impaired general health (8) and
therefore quality of life (QOL) (9–13). Generic,
system-specific, or disease-/condition-specific QOL
measures are available in the literature. System-spe-
cific QOL measures, for example the OHIP-49, have
shown greater specificity and discriminant (known
groups) validity between clinically disparate
groups than generic QOL measures, for example
the SF-36 (14). Condition-specific QOL measures,
which are essentially further reductions/modifica-
tions of system-specific measures, such as
OHIP-EDENT derived from the OHIP-49, have
demonstrated less susceptibility to floor effects and
a comparable responsiveness to change as the
doi: 10.1111/cdoe.12171 461
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longer parent system-specific QOL measure (15). In
addition, above a particular threshold, the reduc-
tion in the number of redundant items has been
shown to improve the OHIP-49’s responsiveness to
changeindisease-/condition-specificsituations(16).
Recent research suggests that OHIP-49 may
contain a number of redundant items, which may
dilute its responsiveness to change in TMDs (9,
17–19). In addition to this, generic instruments like
OHIP-49 may not be sensitive to some of the factors
affecting patients with TMDs (9, 20, 21). A shorter
instrument is desirable for decreased statistical ‘noise’
from redundant items; administration time; complex-
ity of scoring; cost (if used in national surveys) (15).
A shortened condition-specific form of OHIP-49,
OHIP-TMDs, has recently been developed which
contains twenty items from OHIP-49 and two new
items derived from qualitative research with patients
with TMDs, but its psychometric properties have yet
to be examined (9). The aim of this study was, there-
fore, to validate OHIP-TMDs and assess its perfor-
mance as an outcome measure for the management
of TMDs against OHIP-49. The hypothesis was that
in detecting changes in the impact of TMDs on qual-
ity of life, the shortened form (OHIP-TMDs) would
perform as well as OHIP-49.
Materials and methods
Ethical approval was given for this study (National
Research Ethics Service Committee North East 10/
H0907/28), and written informed consent was
obtained from all participants.
Three authors (PY, JD, RW) underwent examiner
(diagnostic) calibration training with the RDC/
TMD, which was periodically rechecked over the
duration of the study to provide an Axis 1 diagno-
sis for any participant included in the study. The
method used was the same as a previously pub-
lished study (22).
The study had four main phases each assessing
different aspects of the validity, responsiveness to
change and reliability of OHIP-TMDs:
• Face and content validity of OHIP-TMDs.
• Responsiveness to change (OHIP-TMDs versus
OHIP-49).
• Known groups (discriminant) validity of OHIP-
TMDs.
• Test–retest reliability of OHIP-TMDs.
Sample
Participants chosen for Phase 1 were consecutive
adult patients undergoing treatment for TMDs in a
University Dental Hospital setting (Newcastle
Dental Hospital) who were returning for review.
For Phase 2, a convenience sample of consecutive
new adult patients referred to the Dental Hospital
with a possible diagnosis of persistent TMDs with
symptoms present for at least 3 months was taken.
Putative participants for Phase 2 were identified
from new patient referral letters from general
dental practitioners that implicitly or explicitly
suggested a diagnosis of TMDs. After telephoning
to gain consent, putative participants were
appointed to the research clinic and underwent a
TMDs examination prior to inclusion in the study.
Participants for Phase 2 were excluded if: on exam-
ination, they did not meet the RDC/TMD criteria
(23) and a diagnosis of TMDs could not be made;
they were found to have other significant comor-
bidities or orofacial pain conditions including
those arising from dental disease; they could not
speak or read English fluently; or they were
edentulous.
Phase 3 symptomless controls were age and gen-
der matched to the Phase 2 patients and were
recruited from TMDs-free individuals who were
accompanying patients in the Dental Hospital
waiting rooms. A validated screening instrument
(24) was used plus three other questions (10) to
exclude any recent: pain, TMDs treatment or per-
ceived treatment need for TMDs.
Phase 4 patients were recruited as a separate
sample in exactly the same manner as patients
recruited for Phase 2.
Instruments
OHIP-49 and OHIP-TMDs were used as self-com-
plete questionnaires.
OHIP-49 is a 49-item problem-based question-
naire with responses recorded on a five-point, ordi-
nal, unipolar scale: never (0), hardly ever (1),
occasionally (2), fairly often (3), very often (4). The
49 items are grouped into common themes cover-
ing 7 domains: functional limitation; physical pain;
psychological discomfort; physical disability; psy-
chological disability; social disability; and handi-
cap. OHIP-49 has been shown to have excellent
psychometric properties, be responsive to change,
and it and its shortened version (OHIP-14) are the
only oral health-related quality of life instruments
used as patient-centred outcome measures in
patients with TMDs to date (10).
OHIP-TMDs is a condition-specific outcome
measure for TMDs derived from OHIP-49 using a
mixed-method qualitative and quantitative
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approach (9). It consists of 22 items covering the
same domains as OHIP-49, twenty of which came
from the original OHIP-49 and two of which
emerged from qualitative research with patients
with TMDs (9). It records responses to the standard
problem-based items of OHIP-49 on the same five-
point ordinal response scale as OHIP-49 with
higher scores indicating a poorer quality of life.
To calculate scores on either of the instruments,
a range of methods are available (25), but no bene-
fits have been shown of one method over another
(26). The simplest method (OHIP-ADD) was used
throughout this study, and it generates a summary
score for the overall instrument by summing the
response codes of the ordinal response scale for
each item across all domains. For the purposes of
the study, we have then divided the total summary
score by the total number of items in the
instrument to yield a score between 0 (best possible
QOL) and 4 (worst possible QOL). This does
not affect the psychometric properties of the scales
and facilitates the direct comparison of the two
instruments when necessary.
After 3 months of treatment participants also
completed a single global transition judgement
question (scale) to assess the degree of perceived
change and as an anchor-based method of assess-
ing the minimally important clinical difference (27).
Participants were asked to score on a Likert scale
whether they felt their condition had improved a
lot (2), improved a little (1), stayed the same (0),
worsened a little (1) or worsened a lot (2).
Phases of study
Phase 1: face and content validity. A focus group
with participants who had RDC/TMD diagnoses
and were undergoing treatment for TMDs was
conducted by a trained facilitator (JD) to specifi-
cally examine the face validity of the two new
questions in OHIP-TMDs and receive general feed-
back on the whole instrument. Discussions from
the focus group were recorded digitally and anon-
ymized. After being transcribed verbatim, they
were participant to a thematic analysis (28).
Five professionals (specialist consultants in
different specialties: oral medicine, oral and maxil-
lofacial surgery, restorative dentistry) familiar with
treating patients with TMDs in a secondary care
Dental Hospital also independently reviewed
whether all items were representative in each
domain of the instrument and gave feedback on
OHIP-TMDs as an instrument. Adequate represen-
tation of each domain in OHIP-TMDs was
considered, and ensured, in the original mixed-
methods development of OHIP-TMDs (9) consis-
tent with the recommendations for item reduction
in OHIP of Awad et al. (16).
Phase 2: responsiveness to change. Those who
agreed to be involved after telephone contact were
sent the study documentation 2 weeks in advance
of their first appointment. This documentation
included either OHIP-TMDs or OHIP-49 to be
completed and sent back prior to attending the
clinic. A permuted block randomization procedure
was used to determine which questionnaire was
administered first. When the patient attended for
their first clinic appointment, they then completed
the other questionnaire in the waiting room prior
to seeing the clinician. Patients therefore had
2 weeks between completing each of the question-
naires (OHIP-49 and OHIP-TMDs) over which
little change in their condition was likely to occur,
but allowed sufficient time to be unlikely to recall
previous responses and bias their response to the
questionnaire administered second. Clinicians were
blinded both to the order of the questionnaires and
their contents throughout the duration of the study.
The association between OHIP-TMDs and OHIP-49
scores, including the impact of questionnaire order,
was investigated using regression analysis.
Following examination and diagnosis, the
patient was given an explanation of the condition,
advice on self-help and initial reversible therapy
selected as appropriate by the clinician. A review
was booked at 3 months to allow sufficient time
for a clinically important change to occur (29). Two
weeks prior to the review appointment, the OHIP-
49 or OHIP-TMDs were similarly re-administered
with the first questionnaire sent to the patient in
the post and the second questionnaire adminis-
tered in the waiting room prior to the review
appointment. At the review appointment, the
patients were also asked to rate the global change
in their condition using an anchor-based method,
in line with IMMPACT recommendations (27, 30),
on a global transition judgement scale (GTJS).
Participants who failed to attend the review ses-
sion or failed to complete their questionnaires were
followed up by phone to encourage them to com-
plete missing questionnaires and return them by
post. Those not responding after two telephone
calls were dropped from the study.
There is little agreement in the literature on sam-
ple sizes for determining responsiveness to change
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(31). Previous research assessing the responsive-
ness of other instruments (32) has used relatively
small sample sizes of 40–50 patients observing
moderate effect sizes ranging from 0.34 to 0.67 for
the summary scores of different instruments whose
intraclass correlation coefficients were in the
acceptable range of 0.59–0.93 (31, 32). We a priori
set our sample size for Phase 2 by examining the
effect sizes with respect to OHIP-49 from previ-
ously unpublished data assessing responsiveness
to change during treatment (29). The effect size
and its confidence intervals were 0.52 (95% CI:
0.27–0.76). As we would expect OHIP-49 to be less
responsive to change than OHIP-TMDs, and given
the intended purpose of the instrument in being
able to detect the smallest effect size required to
show a change in a patient’s quality of life, we
chose a moderate effect size of 0.35 for Cohen’s d
(33) from the lower end of the confidence interval
for OHIP-49. This therefore meant that for a power
of 80% (a = 0.05) we required 67 patients to com-
plete both questionnaires pre- and post-treatment.
To allow for an expected dropout of 33%, as experi-
enced by similar studies (32), we aimed to recruit a
minimum of 100 participants.
Phase 3: known groups validity. People accompany-
ing patients in the Dental Hospital waiting rooms
were approached and invited to take part in Phase
3 of the study. These controls were age and gender
matched to the participants in Phase 2. Screening
questions (10, 24) were used prior to the partici-
pants completing OHIP-TMDs to ensure they were
TMD free, did not have any other painful orofacial
condition and had never had any symptoms of, or
treatment for, TMDs.
Phase 4: test–retest reliability. The participants for
Phase 4 were recruited in the same way as Phase 2.
Each participant completed OHIP-TMDs twice
with a 2-week period between administrations. It
was determined that between 8 and 23 participants
would be required to complete Phase 4 to obtain at
least 80% power for detecting an intraclass correla-
tion coefficient of between 0.6 and 0.8 [‘substantial
agreement’ (34, 35)]. Again to allow for an expected
33% dropout, we aimed to recruit a minimum of 30
participants.
Data analysis
There were no missing data from the control par-
ticipants or the participants in Phase 4. Missing
data were found in <10% of items from each
participant in Phase 2. No participant was there-
fore excluded. Imputation of any missing data fol-
lowed accepted and previously published methods
for OHIP (10, 36). The most common missing items
were logically missing items, given dentate status,
relating to problems with denture fitting and den-
ture comfort. Once these were accepted as logical
and the proportion of missing items per question-
naire (OHIP-TMDs baseline 0.12% missing items,
follow-up 0%; OHIP-49 baseline 0.08%, follow-up
0%) were compared, there was no significant dif-
ference (P > 0.05, test of proportions) in the pro-
portion of missing items between the two
questionnaires.
Data were entered into Excel (Excel v10, Micro-
soft Corporation, Redmond, WA, USA) spread-
sheets and then transferred to the statistical package
STATA (STATA/IC 12 Statistical Software, Stata-
Corp LP, College Station, Texas, USA) for analysis.
Phase 1 – face and content validity. The face validity
of OHIP-TMDs was specifically examined in a
focus group of TMD participants uninvolved with
any other phase of the study, and data from this
group were participant to thematic analysis.
The content validity of OHIP-TMDs was
assessed using the content validity index with the
focus group participants and the health care pro-
fessionals independently. The content validity
index required each item of OHIP-TMDs to be
rated by each participant and by each professional
as to its relevance to TMDs using an ordinal rating
scale where 1 = not relevant at all, 2 = not really
relevant, 3 = quite relevant, 4 = highly relevant.
The content validity index values were then
collapsed to either the individual agreeing (3,4) or
not agreeing (1,2) the relevance of the item. Those
agreeing were scored 1, and those not agreeing its
relevance were scored 0. Each item therefore had a
content validity score, and these scores could be
summed, for each domain, and also for the
entire questionnaire with a higher mean score giv-
ing an indication of greater, perceived, content
validity (28).
Phase 2 – responsiveness to change. Paired, two-
tailed, t-tests were completed on the data to exam-
ine for significant differences between administra-
tions of the questionnaires. The magnitude of
change of the instruments was measured by calcu-
lating the effect size (ES, Cohen’s d) (15, 37) for
each instrument. Confidence intervals for the ES
were calculated using bootstrapping employing
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1000 repetitions and the bias-corrected and acceler-
ated technique (38).
The minimally important clinical difference was
also calculated using methods described by Allen
et al. (39) using the global transition judgement as
the external criterion of change (anchor). Linear
regression was also completed against the global
transition judgement scale.
Cronbach’s alpha was used as a co-efficient of
reliability to measure the internal consistency of
the instruments.
Phase 3 – known groups validity. Independent mea-
sure t-tests of the mean item scores for the control
participants against the mean item baseline scores
of Phase 2 patients completing OHIP-TMDs were
used to determine the known groups validity of
OHIP-TMDs.
Phase 4 – test–retest reliability. Test–retest reliabil-
ity of OHIP-TMDs was determined by calculating
the intraclass correlation coefficient ICC (2,1) using
a two-way random effects model with absolute
agreement according to the Shrout and Fleiss
convention (40).
Results
Face and content validity (Phase 1)
Eight patients were recruited to the focus group,
with five attending on the day. The remaining three
either failed to attend (n = 2) or cancelled due to ill
health (n = 1). The patients ranged from 18 to
69 years and had a wide range of TMDs diagnoses
(Table S1: e-appendix). The results of the thematic
analysis of the patient focus group suggested a
number of small modifications should be made to
OHIP-TMDs before it was used for the main parts
of the study (Phases 2,3,4, final version available in
e-appendix): changed all items with the words
‘jaws, teeth, mouth or dentures’ to ‘jaws, teeth or
mouth’; changed item 3 from ‘painful aching in
your mouth’ to ‘painful aching in your mouth, face
or ear’; changed item 7 from ‘have you felt speech
was painful’ to ‘have you felt talking was painful’.
The patients thought there was ambiguity in
using the word ‘dentures’ as denture users may
have non-TMDs complaints and agreed the
changes to the items as detailed above. There were
no issues raised with the two items in OHIP-TMDs
that were not from OHIP-49 and therefore had not
had their face validity assessed previously.
In addition to the patients involved in the focus
group, five professionals were also independently
involved in assessing the content validity and
cross-checking the patient’s suggested changes for
face validity as above. There were no discordant
responses from the professionals regarding face
validity changes suggested by the focus group.
The content validity index values per domain for
this phase are shown in Fig. S1: e-appendix. The
values per domain for the professionals were gen-
erally closer to 1.0 than the patient’s values, sug-
gesting the professionals felt more of the items
were relevant to TMDs. The overall questionnaire
mean content validity index score for the patients
was 0.64 and for the professionals 0.82. When the
patient and professionals results were combined,
the mean content validity index score for the over-
all questionnaire was 0.73.
The two items where patients and professionals
showed complete agreement on their relevance to
TMDs were as follows:
• ‘Have you had difficulties opening or closing
your mouth?’
• ‘Have you had a sore jaw?’
Responsiveness to change (Phase 2)
A total of 139 patients were invited to take part in
this Phase of the study, with 76 completing it
(Recruitment flow diagram in Fig. S2: e-appendix).
There were 17 patients who failed to complete the
study (classed as noncompleters). The mean age of
these patients was 38.5 years (SD = 14.9). There
was no significant difference between those patients
that completed the study and those that did not in
terms of which questionnaire they received first.
The mean age of the 76 patients who completed
the study was 44.9 years (SD = 15.3), with 86% (65)
of them being women. They had a wide range of
RDC/TMD diagnoses (Table S1: e-appendix). Just
less than half of the sample (43%) had received pre-
vious treatment for TMDs with most of this being
provided in primary care as a soft splint (79%). A
variety of conservative TMDs management was
provided within the study for the whole sample
(Table S2: e-appendix).
In general, mean OHIP-TMDs scores were larger
than mean OHIP-49 scores (Fig. S3a: e-appendix).
The estimated mean difference between OHIP-
TMDs and OHIP-49 summary scores based on a
bootstrap procedure was 0.57 (95% CI: 0.47, 0.66).
Inspection of the plot (Fig. S3a: e-appendix)
suggests that any effect of questionnaire order is
likely to be modest. This was further investigated
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by modelling the relationship between mean
OHIP-TMDs and OHIP-49 summary scores. A
linear relationship between the two instruments
over the full range of possible mean summary
scores (0–4) is clearly not plausible. A second order
polynomial constrained to pass through (0,0) and
(4,4) yielded a reasonably fitting model (R2 = 0.65).
Based on this model, the estimated mean OHIP-
TMDs summary score is plotted as a function
of the mean OHIP-49 summary score in Fig. S3b:
e-appendix. Adding an effect of questionnaire
order to the regression model did not yield a sig-
nificant improvement in fit; the estimated impact
of questionnaire order on the difference between
mean OHIP-TMDs and OHIP-49 summary scores
was 0.01 [95% CI: 0.02, 0.05].
Table 1 shows the mean change scores and the
effect sizes for OHIP-TMDs and OHIP-49 follow-
ing treatment. For both instruments, the change in
score was significant (P < 0.001). The minimally
important clinical difference (MICD) is the smallest
difference (or improvement) in their condition
which patients perceive as being beneficial (41).
Here the MICD was calculated as the mean change
in questionnaire score for the GTJS category
‘improved a little’ (39) as shown in Table 2. Table 3
shows the adjusted coefficient of determination for
change in OHIP-49 and OHIP-TMDs within a lin-
ear regression model against the GTJS examining
whether the patients’ condition had ‘worsened a
lot, worsened a little, stayed the same, improved a
little, improved a lot’ following treatment. The gra-
dient of the line, given by the regression coefficient,
corresponds to the estimated change in question-
naire scores between each category of the GTJS.
Cronbach’s alpha was 0.95 for the baseline admin-
istration of OHIP-TMDs and 0.96 for the follow-up
administration of OHIP-TMDs, which was identi-
cal to the reliability coefficients for baseline, and
follow-up, administration of OHIP-49.
Known groups validity (Phase 3)
There were 76 controls recruited that were age and
gender matched to the patients completing Phase 2.
The mean age of the controls was 46.7 years
(SD = 17.8), with 86% (65) of them being women.
The mean OHIP-TMDs summary score for the con-
trols was 7.38 (SD = 10.1) compared to 33.4 (SD =
17.07) for the patients at baseline. Each individual
item in OHIP-TMDs was significantly different in
score between patients and controls (P < 0.00).
Test–retest reliability (Phase 4)
Twenty patients completed this test–retest Phase
with a mean age of 41.9 years (SD = 20.1). A total
of 85% (17) of these patients were women. Again
patients had a wide range of TMDs diagnoses
(Table S1: e-appendix). The majority (85%) had had
previous treatment for TMDs, with all but one
patient having been seen in primary care for this.
Most of these patients (15; 88%) had been pre-
scribed a soft splint in the past.
The difference in OHIP-TMDs mean summary
scores between baseline and pretreatment follow-up
in this group of patients was 32.4 (SD = 19.0) and 27.9
(SD = 17.5), respectively. The reliability of the obser-
vations for the whole instrument – intra class correla-
tion coefficient (2,1) –was 0.805 (95% CI: 0.565, 0.918).
For purposes of comparability, the treatment that
Phase 2 and Phase 4 patients received after being
examined at Newcastle Dental Hospital is
described in Table S2: e-appendix.
Discussion
It is important that TMDs are studied from a bio-
psychosocial perspective. That is, the biological or
Table 1. Phase 2 mean change scores and effect sizes for
OHIP-49 and OHIP-TMDs
Instrument
Mean raw
change
score (SD)
Mean change
per item (SD)
Effect size
(95% CI)
OHIP-49 11.7 ( 19.4) 0.2 ( 0.4) 0.4 (0.3, 0.6)
OHIP-TMDs 6.9 ( 15.9) 0.3 ( 0.7) 0.4 (0.2, 0.6)
Table 2. Phase 2 mean change score of questionnaires by global transition judgement scale category
Instrument
Global transition
judgement score
1
‘worsened a little’
0
‘stayed the same’
+1
‘improved a little’
+2
‘improved a lot’
OHIP-49 Mean change (SD) 7 ( 16.2) 1.2 ( 14.2) 12.5 ( 16.9) 24.5 ( 17.9)
Mean change per item (SD) 0.1 ( 0.3) 0 (0.3) 0.3 ( 0.3) 0.5 ( 0.4)
OHIP-TMDs Mean change (SD) 9.9 ( 5.1) 1.9 ( 10.8) 6.9 ( 13.1) 17.6 ( 15.7)
Mean change per item (SD) 0.5 ( 0.3) 0.8 ( 0.5) 0.3 ( 0.6) 0.8 ( 0.7)
MICDs shown in bold.
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biomedical concept of how the physical disorder of
TMDs is linked to the psychological and social con-
cepts of how TMDs affect the individual (42, 43).
The biopsychosocial perspective matters because
it is now widely accepted that TMDs are persistent,
recurrent painful conditions, which can be self-lim-
iting and are associated with ‘appreciably distress-
ful, but typically non-specific clinical symptoms’
(42, 43). As such, treatment outcome for TMDs
needs to focus not just on pain reduction, but also
on improving patients’ quality of life.
The negative impact on individuals’ quality of
life by TMDs can be captured by OHIP-49 (13, 18,
19, 44). OHIP-49 is, however, a long questionnaire
with a number of redundant items that may reduce
its responsiveness for TMDs studies (9, 10).
Systematic reviews have repeatedly emphasized
the need for a single, condition-specific instrument
assessing the quality of life of patients with
TMDs. Such an instrument would help reduce
heterogeneity between TMDs trials, allowing more
effective meta-analyses and thereby facilitate
changes in patient management based on best
available evidence.
The new instrument, OHIP-TMDs, validated in
this study generally showed good face and content
validity at both the individual item level and for
the whole instrument. Previous research has indi-
cated the standard criterion for acceptability of the
mean content validity index score for a whole
instrument is 0.8 (28, 45, 46) or 0.9 (47), the overall
result in our study being only slightly less than
this. The mean content validity index score for the
professionals was above the standard (0.82), with
that of the patients being below the standard (0.64).
There was little agreement generally between the
professionals and the patients as to which items
were quite or highly relevant to TMDs. This find-
ing is unsurprising as professionals are likely to
have a better overall understanding of TMD symp-
toms, compared to patients who are likely only to
be able to relate to a specific item if it maps to a
symptom, they have individually experienced.
Furthermore, patients with the same physical TMD
diagnosis may have differing levels of psychosocial
impact (48), and therefore, despite the same physi-
cal diagnosis, the different psychosocial diagnosis
or impacts may make it difficult for seemingly
homogenous patients to agree a consensus on how
TMDs affect their QOL.
Our sample of patients with TMDs chosen to
evaluate responsiveness to change had a broad
spread of TMDs diagnoses (Table S1: e-appendix)
and received a variety of treatments (Table S2:
e-appendix). Regarding responsiveness to change,
the higher magnitude of change with OHIP-49 is
to be expected bearing in mind this instrument
has more than twice as many items as OHIP-
TMDs. However, OHIP-TMDs performed as well
as OHIP-49 in terms of its effect size and associ-
ated confidence intervals (Table 1). Treatment
outcome (Table 2) was also assessed globally
using a GTJS in terms of the patients’ perceptions
of whether their condition had improved, stayed
the same or worsened since starting this latest
episode of treatment. Of the patients reviewed
after 3 months, 53 (70%) reported an improve-
ment with an almost equal division between those
who improved slightly and those who had much
improved. Only seven patients (9%) reported a
worsening of their condition whilst 16 (21%)
reported no improvement. Whilst a GTJS has the
disadvantage of recall bias due to its retrospective
nature (49), it does, however, generate a single
score for comparison against other instruments.
In our study, it is clear that the mean score for
the OHIP-TMDs and OHIP-49 within each of the
five GTJS categories had the expected relation-
ship. This was confirmed with the significant
regression line gradients for both instruments
(Table 3).
The concept of the minimal important clinical
difference (MICD) is one which has been used fre-
quently in medicine in combination with generic
and disease-specific instruments (50), particularly
for assessing chronic pain. It has also been defined
for oral applications, for example for OHIP-20 and
OHIP-14 (32, 39). It is the smallest difference in
scores which patients perceive as either being ben-
eficial or as representing deterioration in their con-
dition (39). The MICD was determined for this
heterogenous group of patients with TMDs using a
recognized method described by Allen et al.
whereby the mean OHIP change score is compared
to GTJS scores for those patients who scored them-
selves as ‘slightly improved’ (39). Whilst the MICD
Table 3. Phase 2 regression coefficient and adjusted R2
values for OHIP-49 and OHIP-TMDs against the Global
Transition Judgement Scale (P = 0 for both question-
naires)
Instrument
Regression
coefficient (95% CI) Adjusted R2
OHIP-49 11.4 (7.3–15.5) 0.29
OHIP-TMDs 9.4 (6.1–12.6) 0.30
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may indeed vary with different TMDs diagnoses,
within either Axis I or II, the MICD score derived
from this study provides an initial estimate for
either instrument which could be applied in clini-
cal trials to allow for analysis of patients by the
proportion of patients who exceed the MICD for
any particular treatment (51, 52). This approach
allows the ‘number needed to treat’ to be calcu-
lated (53) for each treatment group. The ‘Clinically
Important Difference’ (CID) calculated as the mean
of the ‘much improved group’ would give a more
rigorous assessment of treatment outcome. How-
ever, rigour should be tempered by realism as
TMDs can be chronic conditions where patient
management emphasizes improvement rather than
cure.
As can be seen from the gradient of the lines of
the regression analyses, these are close to the
MICD value calculated using Allen’s method, as
described above, for the two instruments, provid-
ing a further estimate of the MICD and the CID.
Other methods, including receiver operator
curves (ROC) (52), have been described to calculate
MICD. The ROC method works well with large
patient groups and could be used in future studies
to corroborate or refine our findings, remembering
that the primary aim of this study was to compare
OHIP-49 with OHIP-TMDs.
OHIP-TMDs showed excellent known groups
validity and good test–retest reliability. As regards
the latter, the ICC showed moderate to high levels
of reliability, with a large confidence interval
around the ICC. This confidence interval is proba-
bly expected as the signs and symptoms experi-
enced by patients with TMDs often fluctuate (54),
especially prediagnosis and pretreatment.
The main limitations of this study relate predom-
inantly to the convenience sample, which reflected
the normal bias towards women in both clinical
and research settings. It is known that responses to
OHIP can differ based on culture and country (36,
55) although in a primarily English speaking cul-
ture, we would hope that OHIP-TMDs would be
largely transferable. We also did not formally con-
duct an Axis 2 RDC/TMD examination and there-
fore cannot directly examine the cohort’s
psychosocial characteristics, but we feel given the
range of responses in the psychosocial domains of
OHIP that our cohort has sampled the broad range
of presentations.
There was a relatively large difference in the
number of patients invited to take part in
the study, compared to those who completed the
study. This is likely due to the fact the design of
the study required a high level of compliance from
patients. Locker et al., (32) similarly had a large
sample size as they expected the numbers of drop-
outs to be high.
This study has highlighted that OHIP-TMDs and
OHIP-49 perform similarly when used as a TMDs
outcome measure. The choice of instrument relates
to its intended purpose. This said, OHIP-TMDs has
less than half the number of items than OHIP-49
and therefore has the advantage of reducing
response burden and potential acquiescence and
attrition bias with cohorts of patients with TMDs.
OHIP-TMDs would also reduce the time involved
in completing instruments if used in a busy clinical
setting. Hence, OHIP-TMDs provides a more
streamlined outcome measure than OHIP-49 for
TMDs treatment trials or evaluation studies. This
more pragmatic approach of using shorter instru-
ments has been advocated by other authors (15,
56).
OHIP-14 is a valid outcome measure to assess
oral health-related quality of life, but it is not a
condition-specific measure for TMDs and is there-
fore not ideal as it is not balanced enough or
domain representative for TMDs (57, 58). OHIP-
TMDs includes all seven domains covered by
OHIP-49 (9) and like OHIP 49 it has been trans-
lated into languages other than English, with the
recent validation of a Chinese version OHIP-
TMDs-C (59). It is important to note, however, that
the recent dimensions of oral health-related quality
of life project have suggested that only the sum-
mary score be used for all versions of OHIP
because of methodological weaknesses in the
domain scoring system (60).
As a final word, the new QOL outcome measure
would of course supplement and in no way replace
accepted pain measurements in clinical trials.
Conclusion
The new patient-centred outcome measure, OHIP-
TMDs, showed good content, face and known
groups validity. It was also responsive to change
and had good test–retest repeatability. OHIP-
TMDs and OHIP-49 were very similar in their
effect size and magnitude of change. Either OHIP-
49 or OHIP-TMDs are appropriate instruments to
measure QOL as a treatment outcome, but OHIP-
TMDs has greater utility being shorter and contain-
ing items specifically relevant to TMDs.
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online version of this article:
Fig. S1.Mean collapsed content validity index scores per
domain of OHIP-TMDs.
Fig. S2. Flow diagram of patients recruited and enrolled
to Phase 2 of the study.
Fig. S3. (a) Mean summary scores dependent on ques-
tionnaire order. (b) Estimated (predicted) mean OHIP-
TMDs score plotted as a function of the mean OHIP-49
score.
Table S1. Summary of the sample TMD Diagnoses of
patients in Phases 1, 2 and 4, as per the RDC/TMD
Groupings, expressed as a percentage of the total num-
ber of patients in that Phase. Patients could have more
than one diagnosis.
Table S2. Treatment prescribed for patients in Phase 2
(n = 76) and Phase 4 (n = 20) per RDC Grouping.
Appendix S1. Full final version of OHIP-TMDs.
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